These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 2533949

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
    Santen RJ, Demers LM, Lynch J, Harvey H, Lipton A, Mulagha M, Hanagan J, Garber JE, Henderson IC, Navari RM.
    J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
    [Abstract] [Full Text] [Related]

  • 26. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
    Häusler A, Schenkel L, Krähenbühl C, Monnet G, Bhatnagar AS.
    J Steroid Biochem; 1989 Jul; 33(1):125-31. PubMed ID: 2527324
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effect of an aromatase inhibitor, 1,4,6-androstatriene-3,17-dione, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat and its mechanism of action in vivo.
    Brodie AM, Brodie HJ, Garrett WM, Hendrickson JR, Marsh DA, Tsai-Morris CH.
    Biochem Pharmacol; 1982 Jun 01; 31(11):2017-23. PubMed ID: 6810900
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of aromatase with CGS 16949A in postmenopausal women.
    Santen RJ, Demers LM, Adlercreutz H, Harvey H, Santner S, Sanders S, Lipton A.
    J Clin Endocrinol Metab; 1989 Jan 01; 68(1):99-106. PubMed ID: 2521224
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
    Kelly PA, Asselin J, Caron MG, Labrie F, Raynaud JP.
    J Natl Cancer Inst; 1977 Mar 01; 58(3):623-8. PubMed ID: 402479
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity.
    Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C, Sánchez-Barceló EJ.
    Int J Cancer; 2006 Jan 15; 118(2):274-8. PubMed ID: 16080194
    [Abstract] [Full Text] [Related]

  • 38. Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors.
    Spinola PG, Marchetti B, Mérand Y, Bélanger A, Labrie F.
    Breast Cancer Res Treat; 1988 Dec 15; 12(3):287-96. PubMed ID: 3147727
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
    Pérez N, Borja J.
    J Int Med Res; 1992 Aug 15; 20(4):303-12. PubMed ID: 1387368
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.